[Targeting of epidermal growth factor receptor and applications in ORL cancer]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) is highly expressed in head and neck squamous cell carcinoma (HNSCC).
• EGFR signaling pathways are crucial for cancer cell proliferation and survival.
• EGFR inhibitors represent a targeted therapy approach for HNSCC.

Purpose of the Study:

• To evaluate the efficacy and safety of EGFR inhibitors as a therapeutic strategy for HNSCC.
• To explore the potential of EGFR inhibitors in combination with chemotherapy (CT) and radiation therapy (RT).
• To define the clinical applications of EGFR-targeted therapies in HNSCC.

Main Methods:

• Review of clinical trials investigating EGFR inhibitors in HNSCC.
• Analysis of treatment outcomes, including response rates and toxicity profiles.
• Exploration of EGFR inhibitor mechanisms of action and potential interactions.

Main Results:

• EGFR inhibitors demonstrated feasibility in clinical administration, acting as cytostatic agents.
• Common side effects included mild skin reactions and digestive symptoms, which resolved post-treatment.
• Response rates were variable, necessitating further investigation through randomized studies.

Conclusions:

• EGFR inhibitors are a viable therapeutic option for HNSCC, particularly in combination with CT or RT.
• Further research is needed to optimize patient selection based on EGFR status and understand complex signaling interactions for enhanced clinical application.